Does SummaCare Cover Vyvanse?

What Is Vyvanse and Why Does Coverage Vary?

Vyvanse is the brand name for lisdexamfetamine dimesylate, a central nervous system stimulant classified as a Schedule II controlled substance by the DEA. The FDA approved Vyvanse for attention-deficit/hyperactivity disorder (ADHD) in children aged 6 and older and adults in 2007, and then for moderate-to-severe binge-eating disorder (BED) in adults in 2015 (FDA prescribing information).

Why Controlled Substances Face Extra Scrutiny

Schedule II stimulants like lisdexamfetamine carry a high potential for misuse. Because of that classification, most commercial insurers and pharmacy benefit managers impose both clinical edits (prior authorization, step therapy) and administrative edits (quantity limits, days-supply caps) that do not apply to non-controlled medications.

SummaCare, a regional health plan headquartered in Akron, Ohio, operates multiple plan types: commercial employer-sponsored plans, individual marketplace plans, and Medicare Advantage products. Each product maintains its own formulary. A drug that sits on Tier 2 in a commercial plan may appear on Tier 4 in a Medicare Advantage plan. Coverage answers are therefore plan-specific, and the information below reflects the general patterns seen across SummaCare products rather than any single contract.

Generic Entry Changed the Field

Takeda's exclusivity on Vyvanse expired, and the FDA granted approval to generic lisdexamfetamine capsules in 2023 (FDA generic drug approvals). Generic versions are bioequivalent to the brand and are typically placed on preferred brand or generic tiers, cutting member cost-sharing substantially compared with brand Vyvanse. If your prescriber wrote "Vyvanse" with no dispense-as-written notation, many SummaCare pharmacy benefits will automatically substitute a generic.

How SummaCare's Drug Formulary Works

SummaCare uses a tiered formulary structure common to most Ohio insurers. Understanding that structure tells you what you will pay before you reach the pharmacy counter.

Formulary Tiers Explained

Most SummaCare commercial plans use a four-to-five tier system:

| Tier | Category | Typical Member Cost | |------|----------|-------------------| | 1 | Preferred generics | Lowest copay (often $0-$10) | | 2 | Non-preferred generics / preferred brands | $20-$45 copay | | 3 | Preferred brand-name drugs | $50-$75 copay | | 4 | Non-preferred brands / specialty | $90-$150+ copay or coinsurance | | 5 | Specialty / high-cost | Coinsurance (25-33%) |

Brand Vyvanse has historically landed on Tier 3 or Tier 4. Generic lisdexamfetamine is typically placed on Tier 2 or Tier 3 once the plan's pharmacy and therapeutics committee reviews it. Actual tier placement can shift each January 1 when formularies reset, so always confirm your current plan year's formulary at summacare.com or by calling member services.

How to Check the Current Formulary

1. Log in to your SummaCare member portal.
2. Manage to "Prescription Drug Benefits" or "Formulary Search."
3. Search for "lisdexamfetamine" (the generic name) to see both brand and generic results at once.
4. Review the tier, any PA or step-therapy requirements, and quantity limits.

The formulary document is also available as a downloadable PDF each plan year. Checking the generic name rather than the brand name ensures you see every covered version.

Prior Authorization Requirements for Vyvanse on SummaCare

Prior authorization (PA) is required for brand Vyvanse on virtually all SummaCare plans and for generic lisdexamfetamine on some plans as well. PA is a clinical review process in which the prescribing provider submits documentation supporting medical necessity.

What the PA Criteria Typically Include

SummaCare's PA criteria for Schedule II stimulants generally align with clinical guidelines from the American Academy of Pediatrics and the American Psychiatric Association. The specific criteria vary by plan year, but common requirements include:

• A confirmed diagnosis of ADHD (based on DSM-5 criteria) or moderate-to-severe BED
• Patient age within the FDA-approved indication (6 and older for ADHD; adults for BED)
• Documentation that the patient has tried and either failed or cannot tolerate at least one formulary-preferred stimulant (see step therapy below)
• Prescriber attestation that the medication is not being used for weight loss or performance enhancement

A PA approval for a controlled stimulant is typically valid for 12 months and must be renewed annually. Some plans require a new PA if you switch from the brand to a generic mid-year.

Step Therapy: The Medications You May Need to Try First

Step therapy requires a trial of lower-tier alternatives before the plan will approve a more expensive agent. For Vyvanse specifically, SummaCare typically requires documented trials of one or two preferred stimulants. Common step-therapy agents include:

• Mixed amphetamine salts (generic Adderall, immediate-release and extended-release)
• Methylphenidate products (Concerta, Ritalin LA, generic equivalents)
• Dextroamphetamine (generic Dexedrine)

A "failed trial" means the patient experienced inadequate symptom control or an intolerable adverse effect during a reasonable treatment period, typically 30 days. Ohio's step-therapy law (Ohio Revised Code 3922.20 et seq.) requires insurers to honor an exception to step therapy if the required medication is contraindicated, previously failed, or if the prescriber documents clinical reasons why the exception is medically necessary.

How to File a PA Request

Your prescriber's office typically initiates the PA. They submit a completed PA request form, along with office notes documenting the diagnosis, prior treatment history, and medical necessity. SummaCare's standard PA turnaround is 3 business days for non-urgent requests and 24 hours for urgent requests. If you need the medication sooner, your provider can request an expedited review by documenting clinical urgency.

What Vyvanse Costs Without Full Coverage

Brand Vyvanse carries a high list price. Without insurance or with a high-tier placement, a 30-day supply of brand Vyvanse 30 mg to 70 mg can exceed $380 at retail pharmacies, though exact prices vary by pharmacy and location.

Manufacturer Savings Programs

Takeda offers a Vyvanse savings card for commercially insured patients. Eligible patients may pay as little as $30 per 30-day fill. The program is not available to patients covered by federal programs such as Medicare, Medicaid, or TRICARE. You can enroll at vyvanse.com or ask your pharmacist.

Generic Lisdexamfetamine Pricing

Generic lisdexamfetamine is substantially less expensive. GoodRx and similar discount programs list 30 capsules of lisdexamfetamine 50 mg at many chain pharmacies for $60 to $120, depending on the dose and pharmacy. If SummaCare's formulary places the generic on Tier 2, your copay with insurance may be lower than a discount card price. Compare both options at the point of sale.

Pharmacy Benefit Manager and Mail-Order Options

SummaCare may contract with a specific pharmacy benefit manager (PBM). Using a preferred network pharmacy or the plan's mail-order service for a 90-day supply can reduce cost per dose. Note that Schedule II controlled substances have additional legal constraints on mail-order dispensing in some states; confirm with SummaCare's pharmacy services line that a 90-day stimulant supply is permitted under your plan and Ohio law.

ADHD and BED: The Clinical Case for Vyvanse

Understanding why a prescriber might specifically request Vyvanse rather than a cheaper stimulant matters when building a PA appeal. Insurers evaluate medical necessity against established evidence.

ADHD Evidence Base

ADHD affects approximately 8.7% of children and 4.4% of adults in the United States, based on population survey data analyzed by the CDC (CDC ADHD data). Lisdexamfetamine's mechanism involves conversion to d-amphetamine after absorption, producing a smoother, longer-lasting effect profile compared with immediate-release amphetamine salts. A randomized, double-blind, placebo-controlled trial published in JAMA Psychiatry (N=414) demonstrated that lisdexamfetamine produced statistically significant improvements in ADHD-RS-IV scores compared with placebo (P<0.001) and showed a clinically meaningful effect size of 0.85 in adult patients (JAMA Psychiatry 2013).

The American Academy of Pediatrics 2019 clinical practice guideline states: "For children 6 years and older, adolescents, and adults, treatment with FDA-approved medications for ADHD, with or without behavioral therapy, is recommended" (AAP guideline).

Binge-Eating Disorder Evidence Base

Vyvanse is the only FDA-approved pharmacotherapy specifically indicated for moderate-to-severe BED in adults. Two key Phase 3 trials (SPD489-343 and SPD489-344, combined N=724) showed that lisdexamfetamine 50 mg and 70 mg produced significantly greater reductions in binge-eating days per week compared with placebo, with 40.0% to 42.0% of lisdexamfetamine-treated patients achieving a cessation of binge days at week 12 versus 14.8% to 21.0% for placebo (NEJM Vyvanse BED data via NEJM.org).

The clinical distinction matters for PA purposes: if the diagnosis is BED rather than ADHD, step therapy with methylphenidate products is clinically inappropriate, because methylphenidate has no evidence base or FDA approval for BED. Your prescriber should explicitly document this distinction in the PA request to prevent an inappropriate step-therapy denial.

What to Do If SummaCare Denies Coverage

A denial is not the final word. Both federal and Ohio state law give you structured appeal rights.

Step 1: Understand the Denial Reason

SummaCare must send a written Explanation of Benefits (EOB) or denial notice specifying the reason. Common denial reasons for Vyvanse include:

• PA not submitted or incomplete
• Step-therapy requirements not met
• Diagnosis code not matching an approved indication
• Quantity or days-supply limit exceeded

Knowing the exact reason shapes the most effective response.

Step 2: File an Internal Appeal

You or your prescriber can file an internal appeal within 180 days of the denial notice for most commercial plans (60 days for Medicare Advantage plans under 42 CFR 423 Subpart M). Submit a letter from the prescriber outlining medical necessity, a copy of relevant office notes, and any peer-reviewed literature supporting the specific clinical scenario. Reference the JAMA Psychiatry or NEJM data cited above if the denial argues that a cheaper alternative is adequate.

Step 3: Request an Expedited Appeal If Clinically Urgent

If a standard review timeline would seriously jeopardize your health, request an expedited internal appeal. SummaCare must respond within 72 hours under CMS guidelines for Medicare Advantage plans and within 72 hours under Ohio's managed care regulations for commercial plans.

Step 4: External Independent Review

If the internal appeal is upheld, Ohio law requires access to an Independent Medical Review Organization (IMRO) review. The Ohio Department of Insurance oversees this process. For Medicare Advantage denials, CMS provides a separate external appeal pathway through the Medicare Appeals process.

Step 5: Ohio Step-Therapy Exception Law

Ohio's step-therapy exception statute (Ohio Revised Code Chapter 3922) obligates SummaCare to grant an exception within 72 hours of a complete request if the prescriber documents that the required step-therapy drug is clinically inappropriate, was previously tried and failed, or if an exception is otherwise medically necessary. This is a state-law right that exists independent of the plan's internal PA process.

SummaCare Medicare Advantage and Part D: Special Considerations

Medicare Part D coverage for Schedule II stimulants has historically been more restrictive than commercial coverage, but CMS policies have evolved.

Part D Formulary Placement

Medicare Advantage plans are required to cover all or substantially all drugs in certain protected drug classes, but stimulants are not a protected class. SummaCare's Medicare Advantage plan formularies may place brand Vyvanse on a non-preferred specialty tier with coinsurance up to 33%, while generic lisdexamfetamine typically sits on a lower-cost tier.

Low-Income Subsidy (LIS) / Extra Help

Medicare beneficiaries who qualify for the Part D Low-Income Subsidy (Extra Help) pay reduced cost-sharing. For 2025, full LIS beneficiaries pay no more than $4.50 per generic fill and $11.20 per brand-name fill, per CMS benchmarks (CMS Extra Help data). If you have Extra Help, the cost difference between brand and generic Vyvanse is small.

Medicare Coverage Gap

Under the Inflation Reduction Act, the traditional Part D coverage gap (donut hole) was eliminated for 2025, and catastrophic out-of-pocket costs are capped at $2,000 annually. This change may lower the effective annual cost of specialty-tier brand Vyvanse for Medicare beneficiaries significantly compared with prior years.

Talking to Your Prescriber and Pharmacist

Navigating insurance coverage for a controlled stimulant is easier when your care team is engaged. Three direct steps can move the process faster.

Ask Your Prescriber to Check Coverage Before Writing

Many electronic health record systems now include real-time pharmacy benefit checks (e.g., through Surescripts). Your prescriber can see formulary placement and PA requirements at the point of prescribing and choose a covered alternative or initiate the PA in the same visit.

Ask the Pharmacist to Run a Coverage Check

Pharmacists can run a test claim before dispensing to identify the tier, copay, PA requirement, or rejection code. A rejection code of 75 (prior authorization required) or 76 (plan limitation exceeded) tells the pharmacist precisely what is needed before the prescription can be filled.

Supply Complete Diagnosis Codes

PA approvals require ICD-10 diagnosis codes. ADHD (unspecified type) is F90.9; combined type is F90.2; BED is F50.81. An incorrect or incomplete code is one of the most common reasons a PA request is denied on the first pass. Confirm with your prescriber's office that the code on the PA request matches the claim code your pharmacy will submit.

Alternatives If Vyvanse Remains Unaffordable

If SummaCare's coverage and the manufacturer savings program still leave Vyvanse out of reach financially, several options exist.

Generic Lisdexamfetamine

This is the most direct substitute. It is the same active ingredient, same doses, same formulation, and is FDA-rated as therapeutically equivalent. Insist on the generic if cost is the primary barrier.

Other Long-Acting Stimulants on the Formulary

Mixed amphetamine salts extended-release (generic Adderall XR) and methylphenidate extended-release products (generic Concerta) are typically on Tier 1 or Tier 2. For most patients with ADHD, these agents produce similar clinical outcomes to lisdexamfetamine, though individual response varies. A 2018 network meta-analysis in The Lancet Psychiatry (N=10,068 participants across 133 trials) found that amphetamine-class drugs generally produced slightly larger effect sizes for ADHD symptom reduction in adults than methylphenidate, with a standardized mean difference of 0.79 versus 0.49 respectively (Lancet Psychiatry 2018).

Patient Assistance Programs

Takeda's patient assistance program (TAP) provides brand Vyvanse at no cost to uninsured or underinsured patients who meet income criteria. Applications are available through the NeedyMeds database or directly from Takeda. Processing times vary, so apply early.

State Pharmaceutical Assistance

Ohio does not have a broad state pharmaceutical assistance program for working-age adults, but county-level resources and federally qualified health centers (FQHCs) may offer sliding-scale fees for both office visits and medications.